I'm going to disagree jeff. IMO, NASDAQ simply CANNOT happen without EUA or some other approval. I'd bet my whole stake on that. If we miss CD12, I'm 99% sure we'll be below the price threshold. On the flip side, with approvals we are almost certain to be on some major exchange in very short order. For the first half of 2021, CD12 determines whether we're a hot biotech on NASDAQ developing numerous indications, or whether we're still having these debates about shorts holding us down and having to raise cash while diluting the shareholders. Everyone has their opinions on our odds with CD12, but the impact seems relatively clear to me one way or the other.